Wave Life Sciences (NASDAQ: WVE) shares preliminary $602M cash balance

Rhea-AI Filing Summary

Wave Life Sciences Ltd. reported a preliminary, unaudited estimate of its cash and cash equivalents, stating that this balance was approximately $602 million as of December 31, 2025. This estimate was included in a press release and an updated corporate presentation made available to the investment community.

The company emphasized that this cash figure is subject to change once full audited financial statements for the year are completed, and any adjustments could be material. Wave Life Sciences also furnished its updated corporate presentation and the related press release as exhibits to this report, while specifying that these materials are being furnished rather than filed for securities law purposes.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

7 Straits View #12-00 false 0001631574 0001631574 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7 Straits View #12-00, Marina One
East Tower Singapore		018936
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 12, 2026, Wave Life Sciences Ltd. (the “Company”) issued a press release and updated its corporate presentation, as described further under Item 7.01 below, each of which included a preliminary, unaudited estimate of the amount of its cash and cash equivalents as of December 31, 2025. The Company preliminarily estimates that its cash and cash equivalents as of December 31, 2025 were approximately $602 million. A copy of the press release and corporate presentation are furnished as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K, respectively.

The information in this Item 2.02 is preliminary, has not been audited and is subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2025. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amount included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025.

Item 7.01. Regulation FD Disclosure.

From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On January 12, 2026, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in these Items 2.02 and 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits relating to Items 2.02 and 7.01 are furnished and not filed:

Exhibit No.		Description
99.1		Press Release issued by Wave Life Sciences Ltd., dated January 12, 2026.
99.2		Corporate Presentation of Wave Life Sciences Ltd., dated January 12, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Kyle Moran
		Kyle Moran
		Chief Financial Officer

Date: January 12, 2026

FAQ

What key financial information did Wave Life Sciences (WVE) disclose in this 8-K?

Wave Life Sciences disclosed a preliminary, unaudited estimate of its cash and cash equivalents, stating this balance was approximately $602 million as of December 31, 2025.

Is the $602 million cash estimate for WVE final and audited?

No. The company stated the $602 million cash and cash equivalents amount is preliminary and unaudited and may change once its audited financial statements for the year ended December 31, 2025 are completed.

What materials did Wave Life Sciences (WVE) furnish along with this cash update?

Wave Life Sciences furnished a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2), both dated January 12, 2026, which include the preliminary cash estimate.

Where can investors find Wave Life Sciences’ updated corporate presentation?

The updated corporate presentation is available on the “Investors” section of Wave Life Sciences’ website at http://ir.wavelifesciences.com/ and is also furnished as Exhibit 99.2.

Are the press release and presentation considered filed documents for WVE?

No. The company stated that the information in Items 2.02 and 7.01, including the press release and presentation, is being furnished and not filed and is not subject to the liabilities of Section 18 of the Exchange Act.

What caution did Wave Life Sciences (WVE) provide about its preliminary cash figure?

Wave Life Sciences cautioned that the preliminary $602 million cash and cash equivalents figure could change after completion of its audited financial statements for the year ended December 31, 2025, and that any changes could be material.